Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

METTL3 drives malignant progression in TP53-mutant prostate cancer.

Molecular biology reports - 11 Nov 2025

Pu Yong, Ye Dan, Dong Nan, Qin Yan, Qi Xiaowei

Abstract excerpt

BACKGROUND: Prostate cancer patients harboring TP53 mutations exhibit a more aggressive and chemo-resistant phenotype. Unfortunately, attempts to identify the vulnerabilities that could be exploited to overcome these aggressive malignancies have made only minimal progress in recent years. Consequently, there is an immediate requirement to investigate novel therapeutic strategies for this subclass. METTL3 complex,...

Topics

Join the communities discussing this publication.

Cell Line, Tumor
Cell Proliferation
Disease Progression
Gene Expression Profiling
Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Methyltransferases

Prostatic Neoplasms

Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41217561
DOI: 10.1007/s11033-025-11160-4
PMCID: PMC12605356

Genes

METTL3
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

METTL3 drives malignant progression in TP53-mutant prostate cancer.PMID 41217561Read ↗

Prognostic Value and Possible Mechanism of m6A Methyltransferase METTL3 in Prostate CancerSemantic proximity Read ↗

TP53 Deficiency in the Natural History of Prostate CancerSemantic proximity Read ↗

Comprehensive analysis of m7G-related Genes METTL1 and WDR4 for predicting prognosis and oncogenic functions in prostate cancerSemantic proximity Read ↗

MTA family of proteins in prostate cancer: biology, significance, and therapeutic opportunitiesSemantic proximity Read ↗

Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer.Semantic proximity Read ↗

Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer.Semantic proximity Read ↗

The Mettl3 epitranscriptomic writer amplifies p53 stress responsesSemantic proximity Read ↗

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.Semantic proximity Read ↗

TLK1-MK5 axis drives prostate cancer cell motility and pathologic features of aggressivenessSemantic proximity Read ↗

PRMT5-exacerbating tumor stemness and immunosuppression confer a novel immunotherapeutic vulnerability in aggressive prostate cancerSemantic proximity Read ↗

METTL5 enhances the mRNA stability of TPRKB through m6A modification to facilitate the aggressive phenotypes of hepatocellular carcinoma cell.Semantic proximity Read ↗

CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.